Manidipine
From Wikipedia, the free encyclopedia
| Systematic (IUPAC) name | |
|---|---|
| 2-[4-(diphenylmethyl)piperazin-1-yl]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ℞ Prescription only |
| Identifiers | |
| CAS number | 89226-50-6 120092-68-4 |
| ATC code | C08CA11 |
| PubChem | CID 4008 |
| ChemSpider | 3868 |
| UNII | 6O4754US88 |
| Chemical data | |
| Formula | C35H38N4O6 |
| Mol. mass | 610.69 g/mol |
| SMILES | eMolecules & PubChem |
Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive[1][2][3][4][5]
Currently Manidipine is marketed by:
-Greek Pharmaceutical group Chiesi Hellas under the brands Manyper, Artedil, Manivasc and Iperten (formerly sold by Torrex Pharma GmbH, now owned by Chiesi Hellas), in Germany, Greece, France, Austria, Spain, Italy and Brazil.
-Takeda Chemical Industries, under the brands Vascoman, Calslot, and Madiplot, in Italy, Japan, Philippines and Thailand.
[edit] References
- ^ Cheer, S.M.; McClellan, K. (2001), "Manidipine: A Review of its Use in Hypertension", Drugs 61 (12): 1777, PMID 11693466, http://drugs.adisonline.com/pt/re/drugs/abstract.00003495-200161120-00010.htm, retrieved 2009-06-20
- ^ McKeage, K.; Scott, L.J. (2004), "Manidipine: A Review of its Use in the Management of Hypertension", Drugs 64 (17): 1923, PMID 15329044, http://drugs.adisonline.com/pt/re/drugs/abstract.00003495-200464170-00011.htm, retrieved 2009-06-20
- ^ Roca-cusachs, A.; Triposkiadis, F. (2005), "Antihypertensive Effect of Manidipine", Drugs 65: 11, PMID 16398058, http://drugs.adisonline.com/pt/re/drugs/abstract.00003495-200565002-00003.htm, retrieved 2009-06-20
- ^ Otero, M.L. (2007), "Manidipine-delapril combination in the management of hypertension", Vascular Health and Risk Management 3 (3): 255, PMC 2293964, PMID 17703633, http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2293964, retrieved 2009-06-20
- ^ Mizuno, Kenji; Hiroshi Haga, Michihiko Takahashi, Soitsu Fukuchi (1992-08), "Evaluation of manidipine hydrochloride, a new calcium antagonist, in the treatment of hypertensive patients with renal disorders", Current Therapeutic Research 52 (2): 248–253, doi:10.1016/S0011-393X(05)80475-8, http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VS8-4GHBHXV-5&_user=10&_coverDate=08%2F31%2F1992&_rdoc=5&_fmt=high&_orig=browse&_srch=doc-info(%23toc%236256%231992%23999479997%23600363%23FLP%23display%23Volume)&_cdi=6256&_sort=d&_docanchor=&_ct=16&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=4a139e549c7d88da59d7ebdfe6f44be7, retrieved 2009-06-20
|
| This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |

